Earnings Call Summary | Syros Pharmaceuticals(SYRS.US) Q1 2024 Earnings Conference
Earnings Call Summary | Syros Pharmaceuticals(SYRS.US) Q1 2024 Earnings Conference
The following is a summary of the Syros Pharmaceuticals, Inc. (SYRS) Q1 2024 Earnings Call Transcript:
以下是锡罗斯制药公司(SYRS)2024年第一季度财报电话会议记录摘要:
Financial Performance:
财务业绩:
Syros reported no revenue in Q1 2024 due to the termination of its collaboration with Pfizer, down from $3 million in Q1 2023.
Syros' R&D expenses fell to $24.7 million in Q1 2024 from $28.8 million the previous year.
Syros' G&A expenses declined to $6.3 million in Q1 2024 from $7.4 million in Q1 2023.
Net loss for Q1 2024 reduced to $3.7 million or $0.10 per share, compared to a net loss of $23.8 million or $0.85 per share in Q1 2023.
Cash position at end of Q1 stood at $108.3 million.
Syros报告称,由于终止了与辉瑞的合作,2024年第一季度没有收入,低于2023年第一季度的300万美元。
赛罗斯的研发费用从去年的2,880万美元降至2024年第一季度的2470万美元。
赛罗斯的并购支出从2023年第一季度的740万美元降至2024年第一季度的630万美元。
2024年第一季度的净亏损降至370万美元,合每股亏损0.10美元,而2023年第一季度的净亏损为2380万美元,合每股亏损0.85美元。
第一季度末的现金状况为1.083亿美元。
Business Progress:
业务进展:
Syros' Phase 3 SELECT-MDS-1 trial achieved a key milestone as it passed a pre-specified interim futility analysis.
FDA granted fast-track designation for tamibarotene for treating Unfit AML with RARA overexpression.
Syros expects to have Phase 2 SELECT-AML-1 trial data by Q3 and pivotal data from the Phase 3 SELECT-MDS-1 trial by Q4.
Syros extended a loan agreement with Oxford that will cover its operational and capital costs into the third quarter of 2025.
Syros 的 3 期 SELECT-MDS-1 试验通过了一项预先规定的中期徒劳分析,从而实现了一个关键的里程碑。
美国食品和药物管理局批准了他米罗汀的快速通道认证,用于治疗具有RARA过度表达的不适合的急性髓细胞白血病。
Syros预计将在第三季度获得第二阶段 SELECT-AML-1 试验数据,在第四季度之前获得第三阶段 SELECT-MDS-1 试验的关键数据。
锡罗斯将与牛津大学的贷款协议延长至2025年第三季度,该协议将涵盖其运营和资本成本。
More details: Syros Pharmaceuticals IR
更多详情: 锡罗斯制药 IR
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示:本文由 AI 生成。无法完全保证内容的准确性。欲了解更多详情,请访问投资者关系网站。本文仅供投资者参考,不构成任何投资建议。